BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, April 11 /PRNewswire-FirstCall/ -- Shire plc will announce first quarter 2006 earnings on Thursday 27 April 2006.
Results press release will be issued at: 12:00 GMT / 07:00 ET Investor conference call time: 14:00 GMT / 09:00 ET Live conference call for investors:
Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the live conference call for investors at 14:00 GMT/9:00 ET.
Please RSVP ssalah@uk.shire.com (T: +44(0)1256-894-160) for this conference call.
The details of the live conference call are as follows: UK dial in 0800-953-1444 (free call) US / Canada dial in US: 1-866-295-3947 (toll free)/ Canada: 1-866-476-5524 International dial in +44(0)1452-561-394 Password/Conf ID 7860599 Live Webcast:
The call will also be available live over the Internet via audio webcast, accessible through www.shire.com in the investor relations section. A slide presentation to accompany the call will also be available on the Shire website.
Replay:
A replay of the presentation will be available for two weeks. Details are as follows: UK dial in 0845-245-5205 International dial in +44(0)1452-55-00-00 Pin code 7860599# Webcast replay www.shire.com, in the investor relations section
If you have any problems accessing this, please contact: Souheil Salah on: +44(0)1256-894160
For further information please contact: Investor Relations Souheil Salah (Rest of the World) +44-1256-894-160 Heidi Wunder (North America) +1-484-595-8970 Notes to Editors: SHIRE Plc
Shire's strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on central nervous system, gastrointestinal, general products and human genetic therapies - all being areas in which Shire has a commercial presence. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. Shire's strategy is to develop and market products for specialty physicians. Shire's in-licensing and merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company's website: www.shire.com.
Shire PlcCONTACT: Investor Relations Souheil Salah (Rest of the World)+44-1256-894-160, Heidi Wunder (North America) +1-484-595-8970
